î
îŒ
ãã°ã€ã³
î
Collplant Biotechnologies Ltd
CLGN0.641USD
-0.019-2.88%
ååŒæé ïŒETïŒ15åé
ãã®æ ªäŸ¡
8.15Mæ䟡ç·é¡
æ倱é¡çŽè¿12ã¶æPER
î
詳现æ å ± Collplant Biotechnologies Ltd äŒæ¥å
CollPlant Biotechnologies Ltd, formerly known as Collplant Holdings Ltd, is a company dealing in aesthetic medicine and regenerative medicine based in Israel. The company provides products and technologies for broadly understood regenerative medicine, including tissue regeneration and organ production. The technology is based on plants and is based on the production of collagen type I (rhCollagen).
Collplant Biotechnologies Ltdã®äŒæ¥æ å ±
îäŒæ¥ã³ãŒãCLGN
äŒç€ŸåCollplant Biotechnologies Ltd
äžå Žæ¥Sep 01, 1993
æé«çµå¶è²¬ä»»è
ãCEOãRotem (Eran)
åŸæ¥å¡æ°57
蚌åžçš®é¡Ordinary Share
決ç®ææ«Sep 01
æ¬ç€Ÿæåšå°4 Oppenheimer Street
éœåžREHOVOT
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœIsrael
éµäŸ¿çªå·7670104
é»è©±çªå·972732325600
ãŠã§ããµã€ãhttps://www.collplant.com
äŒæ¥ã³ãŒãCLGN
äžå Žæ¥Sep 01, 1993
æé«çµå¶è²¬ä»»è
ãCEOãRotem (Eran)
Collplant Biotechnologies Ltdã®çµå¶é£
îäŒç€Ÿå
äŒç€Ÿå/ããžã·ã§ã³
ããžã·ã§ã³
æ ªåŒä¿æ
å€åé¡
Mr. Yehiel Tal
Mr. Yehiel Tal
Chief Executive Officer
Chief Executive Officer
31.14K
--
Dr. Philippe David Bensimon
Dr. Philippe David Bensimon
Vice President - Regulatory Affairs and Quality Assurance
Vice President - Regulatory Affairs and Quality Assurance
2.00K
--
Dr. Oded Shoseyov, Ph.D.
Dr. Oded Shoseyov, Ph.D.
Founder, Chief Scientist
Founder, Chief Scientist
--
--
Mr. Eran Rotem, CPA
Mr. Eran Rotem, CPA
Deputy Chief Executive Officer, Chief Financial Officer
Deputy Chief Executive Officer, Chief Financial Officer
--
--
Dr. Nadav Orr
Dr. Nadav Orr
Vice President - Research & Development
Vice President - Research & Development
--
--
Dr. Ilana Belzer, Ph.D.
Dr. Ilana Belzer, Ph.D.
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Abraham (Avri) Havron, Ph.D.
Dr. Abraham (Avri) Havron, Ph.D.
Independent Director
Independent Director
--
--
Dr. Gili Hart
Dr. Gili Hart
Independent Director
Independent Director
--
--
Dr. Elan Penn, Ph.D.
Dr. Elan Penn, Ph.D.
Independent Director
Independent Director
--
--
Dr. Roger J. Pomerantz, M.D.
Dr. Roger J. Pomerantz, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
詳现ãèŠã
äŒç€Ÿå
äŒç€Ÿå/ããžã·ã§ã³
ããžã·ã§ã³
æ ªåŒä¿æ
å€åé¡
Mr. Yehiel Tal
Mr. Yehiel Tal
Chief Executive Officer
Chief Executive Officer
31.14K
--
Dr. Philippe David Bensimon
Dr. Philippe David Bensimon
Vice President - Regulatory Affairs and Quality Assurance
Vice President - Regulatory Affairs and Quality Assurance
2.00K
--
Dr. Oded Shoseyov, Ph.D.
Dr. Oded Shoseyov, Ph.D.
Founder, Chief Scientist
Founder, Chief Scientist
--
--
Mr. Eran Rotem, CPA
Mr. Eran Rotem, CPA
Deputy Chief Executive Officer, Chief Financial Officer
Deputy Chief Executive Officer, Chief Financial Officer
--
--
Dr. Nadav Orr
Dr. Nadav Orr
Vice President - Research & Development
Vice President - Research & Development
--
--
Dr. Ilana Belzer, Ph.D.
Dr. Ilana Belzer, Ph.D.
Chief Operating Officer
Chief Operating Officer
--
--
åçå èš³
é貚: USDæŽæ°æå»: Tue, Jan 6
é貚: USDæŽæ°æå»: Tue, Jan 6
FY2025Q2
FY2024
FY2024Q2
FY2023
FY2023Q2
FY2022
FY2022Q2
FY2021
FY2020
FY2019
äºæ¥å¥USD
äŒç€Ÿå
åç
æ¯ç
Revenues from the sales of goods
179.00K
0.00%
å°åå¥USD
äŒç€Ÿå
åç
æ¯ç
Northern America
159.00K
88.83%
Europe
20.00K
11.17%
äºæ¥å¥
å°åå¥
äºæ¥å¥USD
äŒç€Ÿå
åç
æ¯ç
Revenues from the sales of goods
179.00K
0.00%
æ ªäž»
æŽæ°æå»: Wed, Feb 25
æŽæ°æå»: Wed, Feb 25
æ ªäž»çµ±èš
çš®é¡
æ ªäž»çµ±èš
æ ªäž»çµ±èš
æ¯ç
Sagy (Ami)
11.36%
Loewenbaum (George Walter II)
8.71%
St. Denis J. Villere & Company, LLC
4.21%
Pinnacle Associates Ltd.
3.87%
Loewenbaum (Lilian Shaw)
2.82%
ä»ã®
69.03%
æ ªäž»çµ±èš
æ ªäž»çµ±èš
æ¯ç
Sagy (Ami)
11.36%
Loewenbaum (George Walter II)
8.71%
St. Denis J. Villere & Company, LLC
4.21%
Pinnacle Associates Ltd.
3.87%
Loewenbaum (Lilian Shaw)
2.82%
ä»ã®
69.03%
çš®é¡
æ ªäž»çµ±èš
æ¯ç
Individual Investor
29.81%
Investment Advisor
7.39%
Investment Advisor/Hedge Fund
5.38%
Hedge Fund
1.70%
Research Firm
0.15%
Family Office
0.13%
Venture Capital
0.11%
Bank and Trust
0.02%
ä»ã®
55.31%
æ©é¢æè³å®¶ä¿ææ ª
îæŽæ°æå»: Mon, Dec 8
æŽæ°æå»: Mon, Dec 8
å ±åæé
æ©é¢æè³å®¶æ°
ä¿ææ ªåŒæ°
æ¯ç
å€åé¡
2025Q4
34
1.82M
18.05%
--
2025Q3
36
1.82M
18.09%
-351.44K
2025Q2
36
2.17M
13.51%
+569.42K
2025Q1
36
2.09M
19.82%
-180.41K
2024Q4
38
2.54M
24.36%
-57.22K
2024Q3
40
2.59M
23.16%
+143.75K
2024Q2
40
2.45M
24.33%
+72.69K
2024Q1
40
2.38M
24.25%
-401.71K
2023Q4
45
2.39M
26.23%
-101.34K
2023Q3
46
2.49M
28.02%
-60.71K
詳现ãèŠã
æ ªäž»åå
îäŒç€Ÿå
ä¿ææ ªåŒæ°
æ¯ç
å€åé¡
å€åç
æ¥ä»
Sagy (Ami)
1.64M
12.81%
-306.10K
-15.75%
Nov 19, 2025
Loewenbaum (George Walter II)
1.26M
9.83%
--
--
Nov 06, 2025
St. Denis J. Villere & Company, LLC
588.72K
4.61%
+41.85K
+7.65%
Sep 30, 2025
Pinnacle Associates Ltd.
507.19K
3.97%
--
--
Sep 30, 2025
Loewenbaum (Lilian Shaw)
406.29K
3.18%
-245.19K
-37.64%
Nov 06, 2025
Evans (Hugh M)
377.43K
2.95%
-1.00
-0.00%
Mar 15, 2025
Roumell Asset Management, L.L.C.
276.43K
2.16%
-38.86K
-12.32%
Jun 30, 2024
AMH Equity, Ltd.
200.00K
1.57%
+39.15K
+24.34%
Sep 30, 2025
Brown Advisory
118.73K
0.93%
+7.55K
+6.79%
Sep 30, 2025
Benjamin F. Edwards & Company, Inc.
39.76K
0.31%
-10.69K
-21.19%
Jun 30, 2024
詳现ãèŠã
é¢é£ETF
îéæå
æ¯ç
ããŒã¿ãªã
é åœé
îéå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã
æ¥ä»
é
åœé
æš©å©ç¢ºå®æ¥
æ¯ææ¥
é
åœèœã¡æ¥
ããŒã¿ãªã
æ ªåŒåå²
îæ¥ä»
é
åœèœã¡æ¥
çš®é¡
æ¯ç
ããŒã¿ãªã
æ¥ä»
é
åœèœã¡æ¥
çš®é¡
æ¯ç
ããŒã¿ãªã
